Krestin

==Nom de la substance==
Krestin, krestine, PSK (polysaccharide K), PSP (polysaccharide-peptide), VPS (versicolor polysaccharide)
==Famille moléculaire==
Polysaccharide (béta-glucane) lié à une protéine
==Source végétale==
* Trametes versicolor (Coriolus versicolor)
==Propriétés==
* Immunostimulant, augmente l'activité des cellules NK natural killers, antitumoral Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treat Rev. 1984 Jun;11(2):131-55. PMID 6238674, Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002 Nov;60(3):258-74. PMID 12436306, Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):275-81. PMID 7606203, Fisher M, Yang LX (2002). Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Research 22 (3): 1737–54. PMID 12168863, Mitomi T, Tsuchiya S, Iijima N, et al. (February 1992). Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Diseases of the Colon and Rectum 35 (2): 123–30. PMID 1735313, inducteur d'apoptose Jiménez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, Garcia-Lora A. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer. 2008 Mar 24;8:78. doi: 10.1186/1471-2407-8-78. PMID 18366723 Texte intégral
==Effet thérapeutique==
* Utilisable en adjuvant du traitement de certains cancers :
** Cancer du sein Iino Y, Yokoe T, Maemura M, Horiguchi J, Takei H, Ohwada S, Morishita Y. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2907-11. PMID 8669887
** Cancer du colon Ohwada, S., Ogawa, T., Makita, F., Tanahashi, Y., Ohya, T., Tomizawa, N., Satoh, Y., Kobayashi, I., Izumi, M., Takeyoshi, I., Hamada, K., Minaguchi, S., Togo, Y., Toshihiko, T., Koyama, T., & Kamio, M. (2006). Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncology reports, 15(4), 861–868. PMID 16525672, Sakamoto, J., Morita, S., Oba, K., Matsui, T., Kobayashi, M., Nakazato, H., Ohashi, Y., & Meta-Analysis Group of the Japanese Society for Cancer of the Colon Rectum (2006). Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer immunology, immunotherapy : CII, 55(4), 404–411. https://doi.org/10.1007/s00262-005-0054-1. PMID 16133112, Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, et al. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum]. Gan To Kagaku Ryoho. 1989 Jun;16(6):2241-9. PMID 2500070
* Immunothérapie adjuvante de certains cancers Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May-Jun;22(3):1737-54. PMID 12168863
==Effets indésirables==
==Bibliographie==
Catégorie:principes actifs